WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

Johnson & Johnson, Novartis and Takeda returned to back the cancer and inflammatory drug developer and were joined by investors including AbbVie, Alphabet and Bristol Myers Squibb.

Softbank enabled the cybersecurity software provider Cybereason to secure crossover financing at a valuation likely to have exceeded $3bn. This year seems set to be a record one for the broader corporate-backed cybersecurity space, with valuations spiking up.

Greenhouse gas monitor GHGSat boosted a Schlumberger-backed round to $45m while Toyota’s Woven Planet subsidiary is buying spatial intelligence software developer Carmera.

The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.

Imperative Care boosted its total funding to at least $379m, with Ascension Ventures participating in the stroke care technology provider's series D round.

Pharmaron, Celgene, Amgen and Merck & Co-backed Imago BioSciences floated in an IPO today, alongside a private placement transaction featuring Pfizer.

Alexandria Venture Investments was among the participants in a series B round for Wugen, which is developing cellular therapeutics for cancer.

SoftBank Vision Fund 2 led a series C round for the driver safety technology developer at a valuation of almost $1bn that also featured M12.

Patient Square Capital led a series B round for the gene therapy developer that included existing corporate investor Dexcel Pharma.